Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Johnson & Johnson Innovation Announces Collaborations with Two Canadian Early-Stage Drug Technology Development Centers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/10/2013 | 02:09pm CEST

Johnson & Johnson Innovation and its affiliate Janssen Inc. in Canada today announced new collaborations with two Canadian early-stage drug technology development centers, Montreal-based NEOMED and Toronto-based MaRS Innovation, to identify and advance promising bio/pharmaceutical technologies that have the potential to impact human health.

Through these collaborations, technical experts from the Johnson & Johnson Innovation Center in Boston, Massachusetts will work with NEOMED and MaRS Innovation to identify investment opportunities emerging from well-validated scientific research discoveries within their communities of academic institutions and biotechnology companies.

"We know from our history of engagement that the Canadian bio/pharmaceutical environment is one of the most vibrant in the world," said Robert Urban, Head of the Johnson & Johnson Innovation Center, Boston. "These new collaborations will allow us to potentially advance important new clinical candidates against disease."

"Quebec and Ontario are home to numerous world-class academic and biomedical research enterprises," said Paul Kershaw, Vice President of Medical Affairs, Janssen Inc. in Canada. "These new relationships with NEOMED and MaRS Innovation are an extension of our commitment to Canada's innovative research community."

NEOMED is a not-for-profit, public-private Pharma alliance dedicated to drug discovery and development. Partially funded by the Ministère des Finances et de l'Économie du Québec, NEOMED is within the NEOMED Institute, a state-of-the-art R&D facility in the Montréal Technoparc.

MaRS Innovation is the commercialization agent for Ontario's discovery pipeline from 16 leading academic institutions. MaRS Innovation is supported by the Government of Canada through the Networks of Centres of Excellence, by the Government of Ontario through the Ontario Centres of Excellence, and by its 16 member institutions.

About Johnson & Johnson Innovation

The Boston Innovation Center is part of Johnson & Johnson Innovation, a division of Johnson & Johnson Finance Corporation. Johnson & Johnson Innovation focuses on accelerating early innovation and enhancing opportunities for collaboration and investment across Johnson & Johnson's global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies focused on early-stage opportunities a one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and diagnostics and consumer companies of Johnson & Johnson. Johnson & Johnson Innovation includes local deal-making capabilities with the flexibility to adapt deal structures to match early-stage opportunities and establish novel collaborations that speed development of those innovations to solve unmet needs in patients. Follow us @jnjinnovation on Twitter. Please visit www.jnjinnovation.com for more information.

About Janssen Inc.

Janssen is dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, metabolic and chronic diseases and women's health. Driven by our commitment to patients, we bring innovative products, services and solutions to people throughout the world. Janssen Inc. in Canada is part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Please visit http://www.janssen.ca for more information.

Johnson & Johnson
John Lacey, 781-392-5514
jlacey1@ITS.JNJ.com
or
Feinstein Kean Healthcare
Jessica Rowlands, 202-729-4089
jessica.rowlands@fkhealth.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
06:09a AADHAR CARD WILL ELIMINATE CORRUPTION : Naidu
06:08a BOJ cuts CPI forecast in quarterly report
06:07a APO ASIAN PRODUCTIVITY ORGANIZATION : and CTA sign agreement to train Medellín productivity practitioners
06:07aDJAUSTRALIA AND NEW ZEALAND BANKING : ANZ Considers Sale of Share Trading Platform
06:06a HK's developer China Resources Land to focus on key cities
06:06a China Aviation Oil net profit soars 48.6% in H1
06:06a BOJ eases policy, expands ETF buying
06:05a EXXON MOBIL : ExxonMobil to Expand Ultra-Low Sulfur Fuels Production at Beaumont Refinery
06:05a OIL & NATURAL GAS : ONGC crude oil output rises 4% in first quarter
06:05a AVANGRID : Construction begins on new substation in South China, Maine
Latest news
Advertisement
Hot News 
0.24%Oil in Bear Market; U.S. Rig Count and BOJ Decision in Focus
Most Read News
07/28 FERRAGOSTO : a sustainable event
07/28 Ford calls an end to U.S. auto boom, rivals bet other way
07/28 Microsoft to cut 2,850 more jobs
Most recommended articles
12:08a BOJ cuts CPI forecast in quarterly report
12:07aDJAUSTRALIA AND NEW ZEALAND BANKING : ANZ Considers Sale of Share Trading Platform
07/28DJMETRO PACIFIC INVESTMENTS : Acquires Philippine Hospital Stake for PHP993.4 Million
07/28DJOil in Bear Market; U.S. Rig Count and BOJ Decision in Focus
07/28 EXCLUSIVE : New York Fed asks Philippines to recover Bangladesh money